BiondVax CEO Issues Letter to Shareholders
30 déc. 2022 07h30 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
BiondVax Announces Closing of $8 Million Underwritten Public Offering
20 déc. 2022 12h42 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and...
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
16 déc. 2022 08h48 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“Company”), which focuses on developing, manufacturing, and commercializing innovative...
BiondVax Regains Nasdaq Compliance
12 déc. 2022 07h06 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
06 déc. 2022 08h30 HE
|
BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
06 déc. 2022 07h30 HE
|
BiondVax Pharmaceuticals Ltd.
Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
30 nov. 2022 09h15 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative...
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
29 nov. 2022 07h00 HE
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
15 nov. 2022 08h33 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...